Status:
COMPLETED
Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery
Lead Sponsor:
University of Novi Sad
Conditions:
Atrial Fibrillation New Onset
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
The study is a prospective, randomized, controlled trial to assess the effects of silymarin on the occurrence of postoperative atrial fibrillation after coronary artery bypass graft surgery.
Detailed Description
Postoperative atrial fibrillation (POAF) is a frequent complication after coronary artery bypass graft (CABG) surgery and is associated with increased mortality. So far, the effects of various drugs a...
Eligibility Criteria
Inclusion
- scheduled for elective CABG surgery using cardiopulmonary bypass
- first cardiac surgery
- left ventricular ejection fraction \> 35%
- less than moderate mitral regurgitation
Exclusion
- preoperative atrial fibrillation
- previous history of interventionally treated arrhythmias
- end-stage renal disease requiring hemodialysis
- chronic inflammatory and neoplastic diseases
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06114719
Start Date
January 1 2023
End Date
September 30 2024
Last Update
December 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiovascular Diseases of Vojvodina
Kamenitz, Serbia, 21204